{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/urticaria/management/managing-urticaria/","result":{"pageContext":{"chapter":{"id":"f797a7bd-9ca9-523b-8f1e-e2afc927c4ab","slug":"managing-urticaria","fullItemName":"Scenario: Managing urticaria","depth":2,"htmlHeader":"<!-- begin field b4cfed8f-11bd-4ea9-abd4-d9722caff49a --><h2>Scenario: Managing urticaria</h2><!-- end field b4cfed8f-11bd-4ea9-abd4-d9722caff49a -->","summary":"Covers the management of people with urticaria.","htmlStringContent":"<!-- begin item 947467ef-d4af-4a56-94fd-031e92363415 --><!-- begin field 32cb6874-de22-49e6-a645-acbd0087ba31 --><p>From birth onwards.</p><!-- end field 32cb6874-de22-49e6-a645-acbd0087ba31 --><!-- end item 947467ef-d4af-4a56-94fd-031e92363415 -->","topic":{"id":"bfdbbcbf-5a56-51b8-b0aa-78a059b4cfec","topicId":"73ccd3ba-b5a5-4a3c-98b2-d838dd8a3c58","topicName":"Urticaria","slug":"urticaria","lastRevised":"Last revised in March 2020","chapters":[{"id":"7068e840-7bdb-5596-a56f-1c930bd4b8c4","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"d6e4cfbd-5e36-5755-a780-8091e4b5f146","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9dde1c08-758f-55bb-b187-0203ded94048","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3daa7b54-d234-587b-8a56-1bb5cae1efe4","slug":"changes","fullItemName":"Changes"},{"id":"54c42276-0c06-5c18-825f-3c440cb30dfe","slug":"update","fullItemName":"Update"}]},{"id":"5cff12c3-445b-5613-bf5d-dc48effe6502","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"9abed54c-a9ed-58d4-bfce-3f0dddd49698","slug":"goals","fullItemName":"Goals"},{"id":"c2f713b4-e2ec-5e5e-be8f-5c4285be0b6e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"e829abf6-8412-500f-9425-647958addf97","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"92b040fe-6318-560a-9ae0-6f98a6aa9c09","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"2d2f38df-88c4-5895-915d-199eefc9b02a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d51180cd-461f-58ad-8f03-20d63965abfb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a7fce165-b445-5aa6-9ec9-6ec8016f4bee","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a5d17f35-ddfe-5931-bfe4-b7dc039baea0","slug":"definition","fullItemName":"Definition"},{"id":"90888c1e-cd37-5fdf-9d0d-b71e51bf56c3","slug":"causes-trigger-factors","fullItemName":"Causes/trigger factors"},{"id":"76d2cc5e-4a3e-5032-8eed-d4010ace1ae7","slug":"prevalence","fullItemName":"Prevalence"},{"id":"507a6931-af71-54ae-a8e7-2b4393c2a41b","slug":"complications","fullItemName":"Complications"},{"id":"091f4740-5801-5ac0-83bd-a7ebbc2a2848","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"fc3a9cf3-3dd4-5456-94e1-90c38c83a0b1","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"513fb45b-36c0-59b5-8f88-13b10509caee","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"e2100cac-0eb7-55e6-b138-9cbc110f1b71","slug":"investigations","fullItemName":"Investigations"},{"id":"2da7bf77-7798-5632-97d4-64d5463f8cde","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"1a1cabda-9d82-5131-8852-db2d844e0b46","fullItemName":"Management","slug":"management","subChapters":[{"id":"f797a7bd-9ca9-523b-8f1e-e2afc927c4ab","slug":"managing-urticaria","fullItemName":"Scenario: Managing urticaria"}]},{"id":"3c7854e6-2fe5-5632-9b63-69f2773b7dd1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"71f6ce5f-ac94-5ef4-9a02-0aa362883a44","slug":"non-sedating-antihistamines","fullItemName":"Non-sedating antihistamines"},{"id":"8888f0f6-7dd8-55fb-afc0-9e5df55b825a","slug":"sedating-antihistamines","fullItemName":"Sedating antihistamines"},{"id":"b8336773-e3de-5ec0-a85b-93fd72ff7869","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"}]},{"id":"c88fe5a9-a559-5661-9a1f-e0ee93078a4d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e9950b4f-8af1-5d4b-b531-431ac4a731bb","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"729aa2a2-070b-51ed-9ecf-c29549914b66","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a30a2a17-7629-5022-a313-848d8264fb35","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f6d1c75a-6a3d-5326-97ca-baff36370740","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"dd5a897e-e7d5-5c98-88b6-35014f9a5dde","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6d27a969-ded2-5d9d-9321-f65e47426edf","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0d45859d-1b50-538f-84fa-568f43b5c283","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1a1cabda-9d82-5131-8852-db2d844e0b46","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"3a64e451-d012-5b2d-b68f-e8d59c3bb4b1","slug":"managing-urticaria","fullItemName":"Managing urticaria","depth":3,"htmlHeader":"<!-- begin field bde1aa29-2997-49ae-811d-b3ef33587a77 --><h3>How should I manage a person with urticaria?</h3><!-- end field bde1aa29-2997-49ae-811d-b3ef33587a77 -->","summary":null,"htmlStringContent":"<!-- begin item 47d5778a-84f8-4785-8e36-4dde062b43b3 --><!-- begin field d2480cd5-c433-4fc9-ac67-bb7851e7d0f5 --><p><strong>For people with urticaria and suspected anaphylaxis</strong> (characterized by features of upper or lower airway obstruction or shock), see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a> for management information.</p><p><strong>For people with urticaria and angio-oedema, </strong>see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a> for management information.</p><p><strong>For all other people with urticaria:</strong></p><ul><li><strong>Identify and manage the underlying <a class=\"topic-reference internal-reference\" href=\"/topics/urticaria/background-information/causes-trigger-factors/\">causes/trigger factors</a> of urticaria, where possible.</strong> <ul><li>If avoidable triggers are identified, given clear instructions on avoidance strategies.<ul><li>If the person is taking a drug associated with chronic urticaria, for example a nonsteroidal anti-inflammatory drug (NSAID), it is prudent for the person to have a trial for at least several weeks without this treatment. </li></ul></li><li>If a cause cannot be identified from the history for people with recurrent or persistent urticaria, consider arranging appropriate <a class=\"topic-reference internal-reference\" href=\"/topics/urticaria/diagnosis/investigations/\">investigations</a>.</li><li>Symptom diaries can be useful as an investigative tool to determine the frequency, duration, and severity of the urticarial episodes. Consider assessing the severity of urticaria using a validated stool, such as the <a data-hyperlink-id=\"d58e1966-deba-4e90-991e-a9920157ef78\" href=\"http://www.itchingforanswers.ca/docs/UAS7-Questionnaire.pdf\">Urticaria Activity Score</a> (UAS7).<ul><li>With the UAS7, the person records the severity of itching and the number of weals daily for 7 days. A score of less than 7 in 1 week indicates control of disease, whereas a score of  more than 28 per week indicates severe disease.</li></ul></li></ul></li><li><strong>For people with mild urticaria </strong><strong>with an identifiable and avoidable cause/trigger,</strong> advise that urticaria is likely to be self-limiting without treatment.</li><li><strong>For people with symptoms requiring treatment:</strong><ul><li>Offer a non-sedating antihistamine (for example cetirizine, fexofenadine, or loratadine) for up to 6 weeks (use clinical judgement to determine the duration of treatment).<ul><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/urticaria/prescribing-information/non-sedating-antihistamines/\">Prescribing information</a> for detailed information on choice and licensed doses of non-sedating antihistamines.</li></ul></li><li>If symptoms are severe, give a short course of an <a class=\"topic-reference internal-reference\" href=\"/topics/urticaria/prescribing-information/oral-corticosteroids/\">oral corticosteroid</a> (for example prednisolone 40 mg daily for up to 7 days) in addition to the non-sedating oral antihistamine.<ul><li>Consider referral if an oral corticosteroid is indicated in a child younger than 16 years of age. </li><li>If rebound symptoms occur, seek specialist advice. Do not repeat the course of oral corticosteroid.</li></ul></li><li><strong>If symptoms improve, </strong>consider the need for further antihistamine treatment, based on an assessment of the underlying cause, and the duration of symptoms before treatment. <ul><li><strong>If it is likely that symptoms will be persistent or recurrent</strong> (for example in people with <a class=\"topic-reference internal-reference\" href=\"/topics/urticaria/background-information/causes-trigger-factors/\">chronic spontaneous urticaria</a>), prescribe daily antihistamine treatment<strong> </strong>for 3–6 months, then review. </li><li><strong>If symptoms were short lived and frequent recurrence thought unlikely, </strong>prescribe treatment to be taken as required or prophylactically (for example prior to occasions when symptoms would be most unwelcome, such as business meetings). </li></ul></li><li><strong>If there is an inadequate response to the first-line antihistamine treatment</strong><strong>,</strong> consider the following options, using clinical judgement:<ul><li>In adults, gradually increase the dose of the first-line antihistamine to up to four times the standard licensed dose (off-label use). Consider seeking specialist advice if this approach is being considered in a child.</li><li>Switch to an alternative non-sedating antihistamine.</li><li>Prescribe a topical antipruritic treatment (such as calamine lotion or topical menthol 1% in aqueous cream) to relieve itch.</li><li>Prescribe an additional sedative antihistamine (such as chlorphenamine) at night, if itch is interfering with sleep. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/urticaria/prescribing-information/non-sedating-antihistamines/\">prescribing information</a> for information on prescribing chlorphenamine.</li><li>Refer the person to a dermatologist or immunologist.</li></ul></li></ul></li><li><strong>Consider assessing the impact of urticaria on the person's quality of life using a validated tool,</strong> such as the <a data-hyperlink-id=\"bd211b62-ca90-4c45-b331-a9920157efd8\" href=\"http://www.itchingforanswers.ca/docs/CU-Q2OL-Questionnaire.pdf\">Chronic Urticaria Quality of Life Questionnaire</a> (CU-Q2oL).<ul><li>The CU-Q2oL is a self-administered, 23-item questionnaire on which the person has to indicate, on a Likert scale with multiple options (1: not at all; 5: very much), how much they have been troubled by each problem, with higher scores indicating worse quality of life.</li></ul></li><li><strong>Arrange referral to:</strong><ul><li><strong>A dermatologist or immunologist for:</strong><ul><li>People with urticaria that is painful and persistent (suspect <a class=\"topic-reference internal-reference\" href=\"/topics/urticaria/diagnosis/differential-diagnosis/\">vasculitic urticaria</a>).</li><li>People whose symptoms are not well controlled on antihistamine treatment. Secondary care treatment options include leukotriene receptor antagonists (montelukast and zafirlukast), cyclosporine, omalizumab, mycophenolate mofetil, or tacrolimus.</li><li>People with acute severe urticaria which is thought to be due to a food or latex allergy.</li><li>People with forms of <a class=\"topic-reference internal-reference\" href=\"/topics/urticaria/background-information/causes-trigger-factors/\">chronic inducible urticaria</a> that may be difficult to manage in primary care, for example, solar or cold urticaria.</li></ul></li><li><strong>A clinical psychologist </strong>for people whose symptoms are adversely affecting their quality of life, for example causing significant social or psychological problems.</li></ul></li><li><strong>Provide additional information on urticaria. </strong>For example:<ul><li>NHS A-Z has useful information on <a data-hyperlink-id=\"3cbdfb6a-0918-4201-96c8-a9920157f010\" href=\"http://www.nhs.uk/conditions/Nettle-rash/Pages/Introduction.aspx\">Urticaria (hives)</a>.</li><li>The British Association of Dermatologists (BAD) has produced an information leaflet on <a data-hyperlink-id=\"8add807b-fa31-4e87-a9c5-a9920157f02d\" href=\"http://www.bad.org.uk/shared/get-file.ashx?id=184&itemtype=document\">Urticaria and Angioedema</a>.</li><li>Allergy UK, a national charity dedicated to supporting allergy sufferers in the UK, has a useful factsheet on <a data-hyperlink-id=\"1e472ec4-1c05-444d-b404-a9920157f03e\" href=\"http://www.allergyuk.org/downloads/factsheets/types-of-allergy/urticaria-and-angiodema.pdf\">Urticaria and Angioedema</a>. It also has a dedicated <a data-hyperlink-id=\"386e637a-e8d3-40f7-bc0d-a9920157f06c\" href=\"http://www.allergyuk.org/getting-help/allergy-uk-helpline\">helpline</a>.</li></ul></li></ul><!-- end field d2480cd5-c433-4fc9-ac67-bb7851e7d0f5 --><!-- end item 47d5778a-84f8-4785-8e36-4dde062b43b3 -->","subChapters":[{"id":"7908cc80-eab9-53ac-971e-7ecd2bce616c","slug":"basis-for-recommendation-403","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 72e829de-0afa-41cd-aed5-5d7a73dc4ac9 --><h4>Basis for recommendation</h4><!-- end field 72e829de-0afa-41cd-aed5-5d7a73dc4ac9 -->","summary":null,"htmlStringContent":"<!-- begin item 403940b0-c99a-420f-8d83-678e18e8806d --><!-- begin field 3f6c5e5c-e554-4362-8ba5-a7a6012ac178 --><p>These recommendations are largely based on <em>The RCPCH care pathway for children with urticaria, angio-oedema or mastocytosis: an evidence and consensus based national approach </em>published by the Royal College of Paediatrics and Child Health (RCPCH) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Leech, 2011</a>]; <em>The diagnosis and management of acute and chronic urticaria: 2014 update </em>published on behalf of the American Academy of Allergy, Asthma, and Immunology (AAAAI), the American College of Allergy, Asthma, and Immunology (ACAAI), and the Joint Council of Allergy, Asthma, and Immunology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Bernstein, 2014</a>]; <em>The EAACI/GA2LEN</em><em>/EDF/WAO  2013 guieline revision and update </em>published by the European Academy of Allergy and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA2LEN), the European Dermatology Forum (EDF), and the World Allergy Organization (WAO) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Zuberbier, 2014</a>]; <em>BSACI guideline for the management of chronic urticaria and angioedema </em>published by the British Society for Allergy and Clinical Immunology (BSACI) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Powell, 2015</a>]; <em>The EAACI/GA2LEN/EDF/UNEV consensus guideline </em>published by the EAACI, the GA2LEN, the EDF, and the urticaria network e.V (UNEV) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Magerl, 2016</a>]; and on expert opinion in review articles on urticaria [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Fitzsimons, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Jafilan, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Marzano, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Termeer, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">BMJ, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Moolani, 2016</a>].</p><h5>Managing urticaria</h5><ul><li>The principles of managing urticaria are similar to those for other mast cell-dependent diseases and are based on elimination/avoidance of the cause/triggers (where possible), symptomatic treatment, patient education, and a personalized management plan [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Bernstein, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Zuberbier, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Powell, 2015</a>].</li><li>The recommendations on nonsteroidal anti-inflammatory drugs (NSAIDs) and symptom diaries are based on expert opinion in the BSACI guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Powell, 2015</a>].</li></ul><h5>Considering using a validated tool, such as the Urticaria Activity Score (UAS7), to assess disease severity </h5><ul><li><p>This recommendation is based on clinical consensus in the EAACI/GA2LEN/EDF/WAO guideline, which highlights that because the signs and symptoms are evaluated by the person with urticaria, the UAS7 is a valuable assessment tool [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Zuberbier, 2014</a>].</p><ul><li>The BSACI guideline does not specifically recommend the use of the UAS7 tool, but states that disease-specific quality of life questionnaires/symptom scores are available for determining the frequency, duration, and severity of urticarial episodes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Powell, 2015</a>].</li><li>Expert opinion in a review article is that the UAS7 tool 'allows for efficient clinical practice, maximizing the information gathered during patient visits while minimizing the use of resources and time' [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Moolani, 2016</a>].</li><li>The Urticaria Severity Score (USS, a 12-question tool) is an alternative tool for monitoring disease severity [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Moolani, 2016</a>].</li></ul></li></ul><h5>First-line treatment with an oral non-sedating histamine H1-receptor antagonist </h5><ul><li>All H1-antihistamines are licensed for use in urticaria. However, based on clinical experience and limited evidence, experts recommend that the non-sedating ones are used first line [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Bernstein, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Zuberbier, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Fitzsimons, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Jafilan, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Marzano, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Powell, 2015</a>].<ul><li>A Cochrane systematic review (search date: June 2014) assessed the effects of H1-antihistamines for chronic spontaneous urticaria (CSU, n = 9759) and found that cetirizine, desloratadine, and levocetirizine are effective when compared with placebo. Loratadine showed no significant difference when compared with placebo [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Sharma, 2014</a>].<ul><li>Adverse effects, such as headache and dry mouth, were tolerable with most antihistamines, but the evidence was less clear for improvement in quality of life (for example reduction in sleep disturbance from itching and less distress from the appearance of hives) as many studies did not address this.</li><li>There was no strong evidence that one non-sedating antihistamine was more effective than the other.</li><li>The authors pointed out that all results were gathered from a few studies or, in some cases, from single-study estimates. The quality of the evidence was affected by the small number of studies in each comparison and the small sample size for many of the outcomes.</li></ul></li></ul></li><li>The recommendation to offer initial antihistamine treatment for up to 6 weeks is based on what CKS considers to be good clinical practice, considering that symptoms of acute urticaria last for less than 6 weeks. In addition, the EAACI/GA2LEN/EDF/WAO guideline recommends waiting 1-4 weeks to allow full effectiveness of a treatment before changing to an alternative treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Zuberbier, 2014</a>].</li></ul><h5>Managing people with severe symptoms</h5><ul><li>Corticosteroids are potent immunosuppressants and can therefore suppress the symptoms of urticaria. Although there are no controlled studies on their use for this indication, their effectiveness is generally accepted and recommended by experts. However, they are only recommended for short periods due to the risk of potentially severe adverse effects (such as diabetes, hypertension, osteoporosis, and gastrointestinal bleeding) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Grattan et al, 2001</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Bernstein, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Zuberbier, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Marzano, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Powell, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">BMJ, 2016</a>].</li><li>The recommended dose and duration of corticosteroid treatment are based on expert opinion in the BSACI guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Powell, 2015</a>].</li></ul><h5>Considering the need for further antihistamine treatment if symptoms improve</h5><ul><li>This recommendation is largely based on the BSACI guideline, which states that once symptom control has been accomplished, daily antihistamine treatment for 3-6 months is advised for most people with CSU, and as required or prophylactic treatment for people with infrequent symptoms [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Powell, 2015</a>].</li><li>The EAACI/GA2LEN/EDF/WAO guideline recommends re-evaluating the need for continued or alternative drug treatment every 3-6 months, as the severity of urticaria may fluctuate and spontaneous remission may occur at any time [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Zuberbier, 2014</a>].</li></ul><h5>Managing inadequate reponse to first-line treatment</h5><ul><li>Incremental updosing of the first-line treatment (up to fourfold higher than the standard licensed dose) is recommended by experts for people who do not respond to standard doses (off-label use) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Bernstein, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Zuberbier, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Fitzsimons, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Marzano, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Powell, 2015</a>].<ul><li>Although there is evidence for this approach [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Zuberbier, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Fitzsimons, 2015</a>], the long-term safety has not been studied and it is not always effective [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Marzano, 2015</a>].<ul><li>The National Institute for Health and Care Excellence (NICE) identified<strong> </strong>2 small randomized controlled trials (RCTs) and 2 double-blind crossover studies (total n = 76) which suggest that cetirizine 20 mg daily (double the standard licensed dose for adults) may improve weals and itching in adults with severe chronic urticaria refractory to standard doses of antihistamines, and appears to be well tolerated. However, symptoms remained in a proportion of people and the studies had many limitations [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">NICE, 2014</a>]. NICE found little information on the use of off-label doses of cetirizine in people aged under 16 years or over 65 years and no data from high-quality studies on the use of cetirizine at doses higher than 20 mg.</li><li>A systematic review and meta-analysis compared the efficacy of antihistamine updosing with standard dosing in people with CSU and found that updosing of non-sedating antihistamines significantly improved control of pruritus but not weal number [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Guill&eacute;n-Aguinaga, 2016</a>]. However, the authors were unable to reach a final conclusion due to the relative weakness of the studies and the significant heterogeneity among them (of the 15 articles included in the final evaluation, only five were assessed as high quality).</li></ul></li><li>Expert opinion in the BSACI guideline and the EAACI/GA2LEN/EDF/WAO<em> </em>guideline is that updosing with a single antihistamine is preferable to mixing different antihistamines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Zuberbier, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Powell, 2015</a>].</li><li>The recommendation to consider seeking specialist advice if updosing is being considered in a child is based on what CKS considers to be good clinical practice, although updosing in children is recommended in guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Zuberbier, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Powell, 2015</a>] and a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Fitzsimons, 2015</a>] on urticaria. </li></ul></li><li>Topical antipruritic treatment is recommended because:<ul><li>Calamine lotion generally soothes itch [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Grattan et al, 2007</a>], although the residue (when dried) can exacerbate itch in some people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">BNF 72, 2016</a>].</li><li>Menthol 1% in aqueous cream is cooling [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Powell, 2015</a>] and is reported to soothe itch [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Greaves and Sabroe, 1998</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Grattan et al, 2001</a>]. One small study in 15 healthy volunteers found that a menthol 1% (in ethanol) solution successfully relieved histamine-induced itching [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Bromm et al, 1995</a>].</li></ul></li><li>Sedating antihistamines are not generally recommended for the treatment of urticaria [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Zuberbier, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Marzano, 2015</a>]. However, some experts advise that they can be considered when itch is interfering with sleep [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Bernstein, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Powell, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">BNF 72, 2016</a>]. They are effective for controlling urticarial symptoms, but their efficacy does not seem superior to non-sedating antihistamines and they have a higher degree of sedation and cognitive impairment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Fitzsimons, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Marzano, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Powell, 2015</a>].</li><li>The recommendation to also consider referral to a dermatologist or immunologist is based on what CKS considers to be good clinical practice.</li></ul><h5>Assessing the impact of urticaria on the person's quality of life</h5><ul><li>The recommendation to consider assessing the impact of urticaria on the person's quality of life (and to monitor disease activity) using a validated tool, such as the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL), is based on clinical consensus in the EAACI/GA2LEN/EDF/WAO guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Zuberbier, 2014</a>].<ul><li>The BSACI guideline does not specifically recommend the use of the CU-Q2oL tool, but states that disease-specific quality of life questionnaires/symptom scores are available for determining the frequency, duration, and severity of urticarial episodes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Powell, 2015</a>].</li><li>Expert opinion in a review article is that the CU-Q2oL tool is an evidence-based tool that 'has been assessed and then validated for determining health status, and used worldwide by both dermatologist and patients for further research in this field' [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Marzano, 2015</a>].</li><li>The Urticaria Control Test (UCT), a retrospective, four-item questionnaire, is an alternative tool that can be used to determine control of disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Moolani, 2016</a>].</li></ul></li></ul><h5>Referral</h5><ul><li>These recommendations are based on what CKS considers to be good clinical practice.</li><li>Information on secondary care treatments is taken from guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Bernstein, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Zuberbier, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Powell, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Magerl, 2016</a>] and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Marzano, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">BMJ, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Moolani, 2016</a>] on urticaria.<ul><li>NICE recommends omalizumab as an add-on treatment for refractory severe CSU in adults and young people aged 12 years [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">NICE, 2015</a>]. See the NICE technology appraisal guidance <em><a href=\"https://www.nice.org.uk/guidance/ta339/chapter/1-guidance\" data-hyperlink-id=\"f7eb4b9d-d015-4b8d-b21d-a99100483cfc\">Omalizumab for previously treated chronic spontaneous urticaria</a> </em>for detailed information.</li></ul></li></ul><h5>Treatments not recommended</h5><ul><li><strong>Topical corticosteroids — </strong>expert opinion in the BSACI guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Powell, 2015</a>] and a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">BMJ, 2016</a>] is that topical steroids have no place in the treatment of chronic urticaria. Although they can reduce weal formation, they can lead to adverse effects due to the need for long-term use over a large surface area [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Kozel and Sabroe, 2005</a>].</li><li><strong>Topical antihistamines —</strong><strong> </strong>there is a risk of sensitization and/or contact dermatitis associated with their use [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Kozel and Sabroe, 2005</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">BNF 72, 2016</a>].</li><li><strong>H2-antihistamines (cimetidine and ranitidine) — </strong>the evidence for their use in urticaria is weak [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Fedorowicz, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Powell, 2015</a>]. Expert opinion in review articles is that since 15% of the histamine receptors in the skin are H2 receptors, H2-antihistamines may provide a small amount of additional benefit to treatment when used in combination with full-dose H1-receptor antagonists [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Fitzsimons, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">BMJ, 2016</a>]. However, this approach is not widely recommended.</li></ul><!-- end field 3f6c5e5c-e554-4362-8ba5-a7a6012ac178 --><!-- end item 403940b0-c99a-420f-8d83-678e18e8806d -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}